Prices are updated after-hours

Professional, Scientific, and Technical Services 2021

Impel NeuroPharma Inc.

IMPL 4 | $0.2411 -77.19% 860K

(0.0% 1d) (0.0% 1m) (-77.2% 1y) (0.0% 2d) (10.1% 3d) (0.0% 7d) (-28.63% volume)
Earnings Calendar: 2024-03-22
Market Cap: $ 5,762,297
https://impelnp.com
Sec Filling | Patents | n/a employees

(US) Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company’s strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD®) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.

parkinson treatment

add to watch list Paper trade email alert is off

Prometheus Biosciences Inc

RXDX | $199.92 0.02% 1.9M

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (3.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-47.11% volume)
Earnings Calendar: 2023-08-09
Market Cap: $ 9,558,822,541
https://www.prometheusbiosciences.com
Sec Filling | Patents | n/a employees

Prometheus Biosciences, Inc. is a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of IBD. The company's precision medicine platform, Prometheus360, combines proprietary bioinformatics discovery methods with one of the world's largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets. Prometheus is headquartered in San Diego, CA.

diagnostics gastrointestinal treatment

add to watch list Paper trade email alert is off

VectivBio Holding AG

VECT | $16.85 0.12% 130K

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (54.9% 1y) (0.0% 2d) (0.2% 3d) (0.0% 7d) (-48.24% volume)
Earnings Calendar:
Market Cap: $ 1,057,156,615
https://vectivbio.com
Sec Filling | Patents | 32 employees

VectivBio is a global, clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions with high unmet medical need. The company is committed to pursuing product candidates with a clear mechanism of action and the potential to meaningfully transform and improve the lives of patients and their families. VectivBio’s product candidate, apraglutide, is a next-generation GLP-2 analog being developed as a differentiated therapeutic for a range of rare gastrointestinal (GI) diseases. Apraglutide is currently being evaluated in a global phase 3 clinical trial as a once-weekly treatment for short bowel syndrome with intestinal failure (SBS-IF).

msa gastrointestinal treatment

add to watch list Paper trade email alert is off

UpHealth Inc

UPH | $0.3 9.13% 0.0% 350K

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (-82.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (3.3% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 5,332,649
https://www.gigcapital2.com
Sec Filling | Patents | 2 employees

(United States) GigCapital Global is a Private-to-Public Equity investment group, sponsoring and operating Special Purpose Acquisition Companies ('SPAC', also known as Blank-Check companies). Founded in 2017 by Dr. Avi Katz, the GigCapital Group and its sponsored SPACs are led by an affiliated team of technology industry experts, deploying a unique Mentor-Investors™ methodology to partner with exceptional privately-held and U.S. and non-U.S. public technology companies led by dedicated, innovative entrepreneurs. The GigCapital Group companies offer financial, operational and executive mentoring to U.S. and global private, and non-U.S. public companies, in order to accelerate their path from inception and as a privately-held entity into the growth-stage as a publicly traded company in the U.S. The partnership of the GigCapital Group with these companies continues through an organic and roll-up strategy growth post the transition to a public company.

msa acquisitions spac blank check

add to watch list Paper trade email alert is off

Convey Holding Parent Inc

CNVY 4 | $10.51 0.0%

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-0.5% 3d) (0.0% 7d) (239.48% volume)
Earnings Calendar:
Market Cap: $ 769,270,737
https://www.conveyhealthsolutions.com
Sec Filling | Patents | 3000 employees

Convey is a specialized healthcare technology and services company that is committed to providing clients with healthcare-specific, compliant member support solutions utilizing technology, engagement, and analytics. Convey's administrative solutions for government-sponsored health plans help to optimize member interactions, ensure compliance, and support end-to-end Medicare processes. By combining its purpose-built technology platforms with dedicated and flexible business process solutions, Convey creates better business results and better healthcare consumer experiences on behalf of business customers and partners. Convey's clients include some of the nation's leading health insurance plans and pharmacy benefit management firms. Convey's healthcare-focused teams help millions of Americans navigate the complex Medicare Advantage and Part D landscape.

optical ycombinator

add to watch list Paper trade email alert is off

Ambrx Biopharma Inc - ADR

AMAM 4 | $28.0 0.0% 1.4M

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (127.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (117.58% volume)
Earnings Calendar:
Market Cap: $ 1,768,206,832
https://ambrx.com
Sec Filling | Patents | n/a employees

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, the company has clinical collaborations with Bristol Myers Squibb, Astellas, BeiGene, Sino Biopharma, Elanco and NovoCodex, for drug candidates generated using Ambrx technology.

urea antibody genetic cardiovascular optical metabolic

add to watch list Paper trade email alert is off

Pear Therapeutics Inc - Class A

PEAR | $0.0292 -38.91% -59.33% 66M

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (-38.9% 7d) (25.47% volume)
Earnings Calendar: 2023-05-15
Market Cap: $ 4,167,984
https://peartherapeutics.com
Sec Filling | Patents | 3 employees

Pear Therapeutics, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program.

treatment

add to watch list Paper trade email alert is off

EQRx Inc

EQRX | $2.34 2.14% 17M

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (26.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (399.91% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 1,141,209,064
https://www.eqrx.com
Sec Filling | Patents | 240 employees

(US) EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States.

treatment

add to watch list Paper trade email alert is off

Pardes Biosciences Inc

PRDS | $2.16 1.37% 2.4M

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (23.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar:
Market Cap: $ 133,945,393
https://www.pardesbio.com
Sec Filling | Patents | 3 employees

Pardes Biosciences is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19. Pardes is applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines. The company’s lead product candidate, PBI-0451, is being developed as a direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, the virus responsible for COVID-19. Pardes Biosciences is on a mission to stop a pandemic and start a movement so patients everywhere can get well sooner.

injection msa antiviral covid

add to watch list Paper trade email alert is off

Embark Technology Inc

EMBK | $2.88 0.35% 0.17% 0

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (9.1% 1y) (0.0% 2d) (0.0% 3d) (0.3% 7d) (-78.02% volume)
Earnings Calendar: 2023-08-10
Market Cap: $ 57,658,450

Sec Filling | Patents | 231 employees

we are developing self-driving semi trucks. we believe that commercial trucking, the backbone of our economy, stands to reap untold benefits by deploying autonomous trucks, particularly during the long haul stretches. roads will be safer. goods will be cheaper. truckers will be called upon to use their skills in new ways while the truck itself becomes a trusted navigation partner. our team is made up of robotics specialists from some of the leading technology companies of our time - with deep expertise in artificial intelligence, machine learning, and real-world deployment of advanced technology. we’re also hiring - contact us if you have the drive to help make the future of autonomous driving a reality today.

add to watch list Paper trade email alert is off

Miromatrix Medical Inc

MIRO | $3.39 3.25% 630K

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (142.1% 1y) (0.0% 2d) (0.0% 3d) (0.6% 7d) (273.61% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 92,951,183

Sec Filling | Patents | 37 employees

miromatrix medical inc. is a life science company that has a novel and proprietary technology to remove cells from, or decellularize, organs and tissues from animal and human sources, facilitating the creation of numerous products, including the potential of fully biological transplantable human organs.

t-cell

add to watch list Paper trade email alert is off

LianBio - ADR

LIAN | $4.92 0.41% 0.41% 410K

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (127.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (40.69% volume)
Earnings Calendar:
Market Cap: $ 531,668,179

Sec Filling | Patents | 2021 employees

lianbio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in china and major asian markets through partnerships that provide access to the best science-driven therapeutic discoveries. lianbio collaborates with world-class partners across a diverse array of therapeutic and geographic areas to build out a pipeline based on disease relevance and the ability to impact patients with transformative mechanisms and precision-based therapeutics.

add to watch list Paper trade email alert is off

Acurx Pharmaceuticals LLC

ACXP | $2.02 -5.16% -5.45% 94K

Professional, Scientific, and T...

(0.0% 1d) (-2.4% 1m) (-33.4% 1y) (-5.6% 2d) (-5.6% 3d) (22.9% 7d) (-34.38% volume)
Earnings Calendar: 2024-03-18
Market Cap: $ 31,829,346
https://www.acurxpharma.com
Sec Filling | Patents | 3 employees

Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. The Company's approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme and its R&D pipeline includes early stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin-Resistant Enterococcus (VRE) and Penicillin-Resistant Streptococcus pneumoniae (PRSP).

injection

add to watch list Paper trade email alert is off

Akoya Biosciences Inc

AKYA | $3.81 -1.04% -1.05% 170K

Professional, Scientific, and T...

(0.0% 1d) (-23.8% 1m) (-47.9% 1y) (0.0% 2d) (0.0% 3d) (-5.2% 7d) (-44.49% volume)
Earnings Calendar: 2024-03-04
Market Cap: $ 187,226,185
https://www.akoyabio.com
Sec Filling | Patents | n/a employees

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers two distinct solutions, the CODEX® and Phenoptics™ platforms, to serve the diverse needs of researchers across discovery, translational and clinical research.

t-cell treatment ceiling

add to watch list Paper trade email alert is off

Alzamend Neuro Inc

ALZN | $0.6894 -0.23% -0.23% 28K

Professional, Scientific, and T...

(0.0% 1d) (-35.2% 1m) (13.3% 1y) (-1.4% 2d) (-1.4% 3d) (-8.2% 7d) (3.58% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 4,734,004
https://alzamend.com/
Sec Filling | Patents | 3 employees

(United States) Alzamend Neuro is a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer’s disease. With its product candidates, the company aims to bring treatments or cures to market at a reasonable cost as quickly as possible. Its current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s. Both of its product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.

treatment msa vaccine t-cell lithium alzheimer neurodegenerative alzheimer’s

add to watch list Paper trade email alert is off

Aerovate Therapeutics Inc

AVTE M | $21.86 1.2% 1.19% 220K

Professional, Scientific, and T...

(0.0% 1d) (-15.2% 1m) (13.0% 1y) (0.0% 2d) (0.0% 3d) (-12.8% 7d) (64.62% volume)
Earnings Calendar: 2024-03-26
Market Cap: $ 609,019,600
https://www.aerovatetx.com
Sec Filling | Patents | 2021 employees

Aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's initial focus is on advancing AV-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or PAH.

treatment

add to watch list Paper trade email alert is off

Biomea Fusion Inc

BMEA | $10.87 -2.6% -2.67% 1.3M

Professional, Scientific, and T...

(0.0% 1d) (-36.2% 1m) (-64.3% 1y) (0.0% 2d) (0.0% 3d) (-13.3% 7d) (114.15% volume)
Earnings Calendar: 2023-11-06
Market Cap: $ 390,117,343
https://www.biomeafusion.com
Sec Filling | Patents | 12 employees

Biomea Fusion, Inc. operates as a biopharmaceutical company. The Company focuseS on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Biomea Fusion serves customers in the United States.

genetic cancer msa

add to watch list Paper trade email alert is off

Compass Therapeutics Inc

CMPX | $1.48 -0.67% -0.68% 230K

Professional, Scientific, and T...

(0.0% 1d) (-34.4% 1m) (-49.5% 1y) (0.0% 2d) (0.0% 3d) (-4.2% 7d) (-67.58% volume)
Earnings Calendar: 2024-03-13
Market Cap: $ 203,631,973

Sec Filling | Patents | 26 employees

compass therapeutics is an antibody discovery and development company focused on comprehensively drugging the tumor-immune synapse with combinations of human monoclonal antibodies, multiclonals, and engineered protein constructs. compass is industrializing antibody discovery and decentralizing biologic validation through a partnership-first mentality that leverages best-in-class technologies and top-tier academic laboratories around the world. novel scientific insights are validated and explored deeply inside our labs before compass pursues the best proprietary combinations of therapeutics into human clinical trials. in 2015, compass quietly closed a $120mm series a financing to fund our ambitious plan to build a fully-integrated biopharmaceutical company from the ground up. our investors are among the most sophisticated venture capitalists in the industry who exemplify our philosophy of building long term economic value only by delivering therapeutics with meaningful efficacy beyond

add to watch list Paper trade email alert is off

Connect Biopharma Holdings Ltd - ADR

CNTB | $1.49 -1.97% -2.01% 32K

Professional, Scientific, and T...

(0.0% 1d) (24.2% 1m) (43.9% 1y) (0.0% 2d) (0.0% 3d) (-7.8% 7d) (-69.63% volume)
Earnings Calendar:
Market Cap: $ 82,056,623
https://www.connectbiopharm.com
Sec Filling | Patents | 2021 employees

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from its T cell-driven research. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα), which is a validated target for the treatment of several inflammatory diseases such as atopic dermatitis (AD) and asthma. Its second lead product candidate is CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1 (S1P1).

ceiling treatment brands antibody t-cell

add to watch list Paper trade email alert is off

Day One Biopharmaceuticals Inc

DAWN 4 | $14.98 -4.89% -5.14% 1.4M

Professional, Scientific, and T...

(0.0% 1d) (-0.7% 1m) (9.2% 1y) (0.0% 2d) (0.0% 3d) (8.0% 7d) (83.74% volume)
Earnings Calendar: 2024-03-04
Market Cap: $ 1,308,909,902
https://dayonebio.com
Sec Filling | Patents | 20 employees

(US) Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers. Day One was founded to address a critical unmet need: children with cancer are being left behind in a cancer drug development revolution. Its name was inspired by the “The Day One Talk”1 that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. The company aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One. Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important emerging cancer treatments. The Company’s lead product candidate, DAY101, is an oral, highly-selective type II pan-RAF kinase inhibitor, and is being evaluated in a pivotal Phase 2 clinical trial (FIREFLY-1) in pediatric, adolescent and young adult patients with recurrent or progressive low-grade glioma (pLGG). The Company’s pipeline also includes the investigational agent pimasertib, a clinical-stage, oral, small molecule found to selectively inhibit mitogen-activated protein kinase kinases 1 and 2 (MEK). Through Day One and its collaborators, cancer drug development comes of age. Day One is based in South San Francisco.

treatment diagnostics cancer

add to watch list Paper trade email alert is off